The enhancer pioneer transcription factor FoxA1 is a global mediator of steroid receptor (SR) action in hormone-dependent cancers. In castration-resistant prostate cancer (CRPC), FoxA1 acts as an androgen receptor co-factor to drive G2-M phase cellcycle transit. Here we describe a mechanistically distinct SR-independent role for FoxA1 in driving G1-S phase cell-cycle transit in CRPC. By comparing FoxA1 binding sites in prostate cancer cell genomes, we defined a co-dependent set of FoxA1-MYBL2 and FoxA1-CREB1 binding sites within the regulatory regions of the Cyclin E2 and E2F1 genes that are critical for CRPC growth. Binding at these sites upregulate the Cyclin E2
Introduction
The FoxA subfamily of winged helix/forkhead box (Fox) transcription factors, which consists of three members, FoxA1, FoxA2 and FoxA3, have been found to play important roles in multiple stages of development, metabolism, differentiation and proliferation (1) .
FoxA proteins function as "pioneer factors" that engage chromatin before other transcription factors (2-5). Recent studies have further shown that FoxA1 functions as a pioneer factor for steroid hormone receptors (SR), including androgen receptor (AR) in prostate cancer cells and estrogen receptor (ER) in breast cancer cells, directing AR-and ER-regulated, hormone (androgen and estrogen)-responsive genes (6) (7) (8) . These studies further suggested that FoxA1 acts upstream of AR and ER to regulate their target genes in hormone-dependent prostate and breast cancers.
In both androgen-dependent prostate cancer (ADPC) and fatal, castration-resistant prostate cancer (CRPC), AR expression and functionality has been well documented (9), but the receptor appears to play different roles in the two diseases. For example, in ADPC, AR functions primarily to promote G1-S cell-cycle progression, by transcriptional and/or post-transcriptional regulation of CDKN1A, CCND1 and CDKN1B (10). However, in CRPC, the primary function of AR appears to be regulation of G2-M transition. Thus, the receptor appears to be "reprogrammed" to direct transcriptional regulation of G2-M phase-specific genes, including UBE2C and CDK1 8 length varied from 6 nt to 15 nt. Significantly enriched motif was annotated using STAMP (24) .
Results

FoxA1 promotes CRPC cell growth by driving both G1-S and G2-M cell-cycle progression
Our previous findings that FoxA1 binding at the enhancer regions of several cell-cycle G2-M phase genes (e.g. UBE2C and CDK1) is required for overexpression of these genes in CRPC (11) prompted us to further examine the functional role of FoxA1 in CRPC. We first tested the effect of FoxA1 silencing on cell proliferation in abl, a CRPC cell line that closely models clinical CRPC (11, 12, 25). Short interfering RNAs (siRNAs) targeting FoxA1 (two independent siRNAs) were transfected into abl. Both siRNAs dramatically reduced cellular FoxA1 levels (Fig. 1A) , and significantly decreased androgenindependent cell proliferation of abl (Fig. 1A) . The inhibitory effect of FoxA1 silencing on cell proliferation was also observed in CWR22Rv1 ( Supplementary Fig. S1A ), another CRPC cell model (26). We next examined the effect of FoxA1 silencing on CRPC cell-cycle progression using a thymidine-nocodazole block in order to enrich abl cells at mitosis (15) . Consistent with the role of FoxA1 in the upregulation of cell-cycle G2-M phase genes in CRPC cells (11), FoxA1 silencing caused a G2-M accumulation in the treated abl cells (Fig. 1B) . However, FoxA1 knock down resulted in a G1-S block in unsynchronized abl and CWR22Rv1 cells ( Fig. 1C and Supplementary Fig. S1B ), suggesting that FoxA1 promotes both G1-S and G2-M progression in CRPC cells. As a major role of AR in CRPC is to upregulate G2-M phase gene expression and promote the G2-M transition (11), these data further indicate that the ability of FoxA1 to promote G1-S progression is an AR-independent phenomenon. In agreement with our previous findings (16), silencing of FoxA1 had no effect on dihydrotestosterone (DHT)-stimulated LNCaP G1-S progression and cell proliferation ( Supplementary Fig. S1C and S1D ).
Taken together, these data suggest that FoxA1 is required for androgen-independent but not androgen-dependent growth of prostate cancer.
FoxA1 upregulates G1 phase genes CCNE2 and CCNA2 to enhance CRPC cell growth
To identify FoxA1-regulated genes that contribute to FoxA1-mediated G1-S transition in CRPC cells, abl cells were transfected with siFoxA1 and a control siRNA (siControl), cultured for 72 hours, and analyzed for expression of the G1 phase genes CCNE2, CCNA2, CCNE1, CDK2, CDK4, CDK6, CCND1, CCND2, CCND3, CDKN1A, and CDKN1B and RB. LNCaP cells transfected with these siRNAs and treated with DHT (10 nM) for 4 hours and 24 hours served as controls. Among the eleven genes examined by qRT-PCR, expression levels of CCNE2, CCNA2 and CDK2 were higher in abl cells transfected with siControl compared to similarly transfected, untreated or DHT-treated LNCaP ( Fig. 2A) , although CCNE2, CCNA2 and CDK2 expression levels were increased after DHT treatment of LNCaP cells ( Fig. 2A) (27) . Silencing of FoxA1 markedly decreased CCNE2 and CCNA2 but not CDK2 expression in abl but not LNCaP cells ( Fig.   2A ). Importantly, re-analysis of gene expression profiles from three independent clinical studies (17-19) confirmed that expression of CCNE2 and CCNA2 was greater in cases of CRPC compared to ADPC (Fig. 2B) . Western blot analysis demonstrated that CCNE2 and CCNA2 protein levels were also greater and FoxA1-dependent in abl than LNCaP cells, in the presence or absence of DHT (Fig. 2C) . Consistent with previous reports showing that CCNE2 and CCNA2 binding and activation of CDK2 lead to RB phosphorylation (28, 29) , FoxA1-enhanced expression of CCNE2 and CCNA2 protein increased FoxA1-dependent expression of phosphorylated CDK2 and phosphorylated RB in abl versus LNCaP (Fig. 2C) . The inhibitory effect of FoxA1 depletion on mRNA and protein expression levels of CCNE2 but not CCNA2 was also observed in CWR22Rv1 cells ( Supplementary Fig. S2A ).
We next examined the functional role of CCNE2 and CCNA2 in ADPC and CRPC cell growth. In cell proliferation assays, CCNE2 or CCNA2 silencing markedly decreased abl and CWR22Rv1 growth ( Fig. 2D and Supplementary Fig. S2B ), suggesting that CCNE2 and CCNA2 play an essential role in CRPC cell proliferation. To test whether differences in expression of CCNE2 and CCNA2 were responsible for androgen-independent and androgen-dependent phenotypic differences between abl and LNCaP cells, we generated LNCaP cell lines stably expressing CCNE2 or CCNA2. Consistent with a previous report that overexpression of G1 cyclins was not sufficient to induce LNCaP growth in the absence of androgen (30), no effect of CCNE2 or CCNA2 overexpression on cell proliferation and G1-S progression was observed for vehicle-treated LNCaP cells ( Fig.   2E and Supplementary Fig. S2C ). However, while DHT treatment (1 nM or higher) LNCaP and abl cells were transfected with siControl or siFoxA1 followed by FAIRE. In siControl transfected cells, a higher FAIRE signal was observed at the CCNE2 enhancer and promoter regions in abl cells than in LNCaP cells (Fig. 4D) , and importantly, FoxA1 silencing decreased FAIRE enrichment at the CCNE2 enhancer and promoter regions only in abl cells (Fig. 4D) . Taken together, these data strongly indicate that increased Fig. S4B ).
CRPC-specific FoxA1 binding sites upregulate CCNA2 via E2F1
Although, in general, FoxA1 binding was significantly enriched near overexpressed genes in CRPC compared with ADPC (Fig. 3B ), we were unable to identify, using the ChIP-on-chip technique, abl-specific FoxA1 binding sites near CCNA2 (Fig. 5A), indicative of an indirect mechanism of FoxA1-mediated CCNA2 upregulation in abl cells ( ( Fig. 5A and 5B), we hypothesized that FoxA1 may regulate CCNA2 expression through a direct upregulation of E2F1. As expected, increased levels of H3K4me1 and p-Pol II, higher occupancy of CBP and MED1, and higher FAIRE enrichment at E2F1 enhancers, were observed in abl compared to LNCaP cells ( Fig. 5C and 5D ), resulting in FoxA1-dependent, increased mRNA and protein levels of E2F1 in abl versus LNCaP cells in the absence of androgen (Fig. 5E ). Similar to CCNE2 regulatory regions, no AR binding was observed at these two E2F1 enhancers in abl cells (data not shown). We next performed ChIP to examine whether E2F1 directly regulates CCNA2 in abl cells, and expression of CCNA2 mRNA following E2F1 silencing was also examined in LNCaP and abl cells. As shown in Figure 5F and 5G, E2F1 binding at the CCNA2 promoter was increased, and E2F1-dependent, CCNA2 mRNA expression was greater in abl versus LNCaP in the 
MYBL2 and CREB1 protein levels were higher in abl versus LNCaP cells (Fig. 6B) , and ChIP assays showed greater recruitment of MYBL2 and CREB1 to regulatory regions of the abl-specific, FoxA1 target genes CCNE2, E2F1, UBE2C and CDK1 ( (Fig. 6D and Supplementary Fig. S5B, S5C ). In addition to decreased FoxA1 binding, ChIP analyses further demonstrated that MYBL2 and CREB1 silencing reduced p-Pol II levels on most enhancers and promoters of abl-specific FoxA1 target genes, similar to the effect of FoxA1 silencing itself (Supplementary Fig. S5D ).
Collectively, these results demonstrate that MYBL2 and CREB1 significantly alter Fig. S6B ). These data suggest that FoxA1-MYBL2 or -CREB1 codependently bind to the same regulatory elements of abl-specific FoxA1 target genes.
To further investigate the molecular mechanisms for the co-dependent binding of FoxA1-MYBL2 and -CREB1 on chromatin, we examined the effect of their silencing on histone acetylation. Altered chromatin structure can greatly influence transcription factor access to chromatin, and histone acetylation has been shown to have profound effects on chromatin architecture leading to a decrease in inter-nucleosomal interaction (33, 39) .
LNCaP and abl cells were transfected with siRNAs targeting FoxA1, MYBL2 or CREB1, and ChIP assays were performed using an antibody against acetylated histone H3 (AcH3). Silencing of FoxA1, MYBL2 or CREB1 reduced AcH3 levels at regulatory sites of abl-specific FoxA1 target genes in abl but not LNCaP cells, and the level of AcH3 reduction was similar to CBP (a potent histone acetyltransferase [HAT]; positive control) silencing ( Fig. 6F and Supplementary Fig. S6C ), suggesting that these three transcription factors, possibly via recruitment of CBP and other HATs, can significantly induce histone acetylation, leading to nucleosome disruption at FoxA1 target gene regulatory regions specifically in abl cells (Fig. 4D, 5D and 6G and Supplementary Fig. S4B and S6D ). Although silencing of MYBL2 and/or CREB1 decreased CCNE2, E2F1, CCNA2, UBE2C and CDK1 mRNA levels in LNCaP cells to some extent, in abl cells, knocking down of these two transcription factors greatly reduced mRNA expression of these ablspecific FoxA1 target genes ( Fig. 6H and Supplementary Fig. S6E ). As anticipated, slower growth of siMYBL2-or siCREB1-transfected CRPC cells was observed versus siControl ( Fig. 6I and Supplementary Fig. S6F ), presumably due to decreased expression of the five essential cell-cycle genes, indicating that MYBL2 and CREB1 are critical for abl-specific FoxA1 target gene expression and CRPC cell growth.
DISCUSSION
In the present study, we found that in addition to its known role as an AR collaborator in regulating CRPC-specific, AR target G2-M gene transcription and thus a driver of G2-M cell-cycle progression (11) ( Fig. 1 and Supplementary Fig. S4-S6 ), FoxA1 directs CRPC G1-S cell-cycle progression through direct regulation of CCNE2, and indirect regulation of CCNA2 via E2F1 (Fig. 2, 4 and 5) . These findings establish a previously undescribed yet essential role for FoxA1 as a master cell-cycle regulator, required for both G1-S and G2-M progression in CRPC, whereas AR is mainly involved in promoting cell-cycle G2-M but not G1-S transition in CRPC (Fig. 7) (11, 40) .
The findings that an abl-specific FoxA1 cistrome promotes both G1-S and G2-M cellcycle progression, through transcriptional regulation of non-AR target genes (CCNE2 and E2F1) (Fig. 4 and 5) and AR target genes (UBE2C and CDK1) ( Supplementary Fig. S4 Interestingly, the expression of MYBL2 and CREB1 is not only increased in abl compared with LNCaP (Fig. 6B) 
ADPC (43, 44
). By contrast, strong FoxA1 protein expression persists in early-and latephase of prostate cancer (Fig. 1A) (45, 46) , suggesting that increased expression and binding of MYBL2 and CREB1 during prostate cancer progression alter FoxA1 genomic binding, leading to CRPC-specific upregulation of critical G1-S and G2-M cell-cycle genes by FoxA1 (Fig. 7) . Therefore, MYBL2 and CREB1 may serve as new therapeutic targets for CRPC.
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